Journal Guide

Despite the major efforts made in oncology over the past ten years, only relatively modest improvements have been made in the conventional treatment of cancer. Recently, a better understanding of molecular pathways has provided pathologists with clues to the parthenogenesis of the disease and multiple targets for new strategies. New treatments, monoclonal antibodies or small molecules, have emerged targeting these pathways and inhibiting tumor growth and progression. These 'mabs' and 'nibs' constitute a new language with its own grammar that oncologists have to learn. Significant work remains in controlling theses processes and understanding these new compounds. This journal aims to be a pragmatic tool for all physicians committed to the field, focusing on insight into the basic science of cellular functions, critical reviews of clinical data. The Société française d'angiogenèse is affiliated to the journal.

Technology in Cancer Research and Treatment (TCRT) welcomes manuscripts from active investigators involved in technologies devoted to early diagnosis, treatment, and palliation of cancer. TCRT will include both experimental and theoretical investigations. Among the topics that will be covered are MRI, including functional MRI, spiral CT, PET, optical spectroscopy, computer-aided reconstruction of tumors, computer-aided drug design, stereotactic radiosurgery, cryosurgery, brachytherapy, electroporation, photodynamic therapy, gene therapy, cancer vaccine, proteomics, and genomics, as they impact cancer research and treatment. Special emphasis will be given to non-invasive techniques. TCRT publishes original articles, express communications, opinion pieces, and timely reviews. No case report or a single institute experience will be considered for publication.

The Breast is an international, multidisciplinary journal for clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention and therapy. The Editors welcome the submission of original research articles, systematic reviews, viewpoint and debate articles, and correspondence on all areas of pre-malignant and malignant breast disease, including:• Surgery• Medical oncology and translational medicine• Radiation oncology• Breast endocrinology• Epidemiology and prevention• Gynecology• Imaging, screening and early diagnosis• Pathology• Psycho-oncology and quality of life• Advocacy• Supportive and palliative care• NursingThe Breast is a valuable source of information for surgeons, medical oncologists, gynecologists, radiation oncologists, endocrinologists, epidemiologists, radiologists, pathologists, breast care nurses, breast cancer advocates, psychologists and all those with a special interest in breast cancer.

The Journal of Pathology aims to serve as a translational bridge between basic biomedical science and clinical medicine with particular emphasis on, but not restricted to, tissue based studies. The main interests of the Journal lie in publishing studies that further our understanding the pathophysiological and pathogenetic mechanisms of human disease.

The Lancet Oncology is recognized for providing a global, authoritative, and independent forum for the highest quality clinical oncology research and opinion. With an impact factor of 25.12, the journal ranks third out of 194 oncology journals worldwide, is the leading clinical research journal in oncology, and is in the top 0.5% of all scientific journals, of any discipline, globally (2012 Journal Citation Reports®, © Thomson Reuters 2013).The Lancet Oncology publishes original research, reviews, personal views, commentaries, and news across the global field of oncology. The journal is stringently edited and peer-reviewed to ensure the scientific merit and clinical relevance of its diverse content. All original research is fast-tracked to publication within 8 weeks of submission and published first online on TheLancet.com before the print issue. Articles published in The Lancet Oncology regularly receive coverage in the mainstream print, online, and broadcast media.Visit www.TheLancet.com to find out more about The Lancet Oncology.

Oncology and hematology professionals are continuously charged with staying on the cutting–edge of new medical treatments and technologies to foster better cancer patient care and practice management. To that end, The Oncologist® is dedicated to translating the latest research developments into best multimodality practice.Established by oncologists for oncologists, the Journal is committed to helping physicians excel in a challenging and ever-changing environment; to ensure their patients’ rights to the highest level of care from screening and prevention to diagnosis, treatment and management of the disease.Designed specifically for the busy practitioner, The Oncologist is devoted to medical and practice issues for surgical, radiation, and medical oncologists. With emphasis on clear, concise interpretation, rather than data, the Journal's articles are meant to impact the practice of oncology and to facilitate significant communication in the introduction and application of new advancements.The Oncologist'sSenior Editors believe that the various oncology subspecialists should share the same information base and read the same journal. It is up to us, as leaders in this field, to defend the patient's needs and rights and to assure that the patient has an advocate. In order to do so, we have to be united and fully informed. We pledge to put the best and latest information on cancer management before our readership, to help prepare them for the future, and to do their best as a team to improve outcomes and quality of life for every patient.Manuscripts are reviewed by two or more field experts and, when accepted, are published expeditiously—generally within 12 weeks. When a contribution is of such relevance as to significantly impact public health, authors may request Fast Track Review for a Rapid Communication, in which case an editorial decision will be made within 2 weeks of submission.The Oncologist challenges its readers to understand what is new and better, to glimpse the future, not only in terms of research, but also in terms of new team approaches to disease management. In short, we want our readers to explore how cancer medicine could be and will be practiced now and throughout the 21st century.CORRESPONDENCEEditorial correspondence, including submissions for publication or letters to the Editor, should be addressed to the Executive Editor. Submissions for publication in the Fundamentals in Cancer Medicine section should also be addressed to the Executive Editor.Information for Authors can be found at the back of each issue, or contact the AlphaMed Press Editorial Office.Advertising: Correspondence and rate requests should be addressed to the Publisher.Change of Address notices: Both the subscriber's old and new address should be e-mailed to AlphaMed Press at least one month in advance. You can also mail the information to: AlphaMed Press, c/o Cambey & West, PO Box 412, Congers, New York 10920-9914 USA.

The Journal is aimed at researchers and clinicians involved in the medical treatment of cancer and is a forum for publishing original research and reviews in this area. It will cover systemic cancer treatments including chemotherapy, endocrine therapy, biological therapy and immunotherapy, as well as adjuvant systemic therapy. All cancers will be covered including gynaecological cancers, lung cancer, gastrointestinal cancers, urological cancers, head and neck cancers, and skin cancer.

Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.

Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.Benefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com